This document outlines details of PBS-subsidised tocilizumab for patients with active Giant cell arteritis (GCA).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure of how to action an application.
Giant cell arteritis (GCA) quick reference
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial PB272 form Patients aged 50 years or older | Written Electronic S85: tocilizumab | No | OPA | Must be treated by a: - rheumatologist
- clinical immunologist
- neurologist experienced in the management of GCA
| Yes |
Continuing | Telephone Electronic S85: tocilizumab | No | OPA | Must be treated by a: - rheumatologist
- clinical immunologist
- neurologist experienced in the management of GCA
| Yes |
Expand all